Journal
CIRCULATION JOURNAL
Volume 74, Issue 3, Pages 390-404Publisher
JAPANESE CIRCULATION SOC
DOI: 10.1253/circj.CJ-09-0923
Keywords
Cardiac function; Cells; Ischemic heart disease; Myocardial infarction; Reperfusion
Categories
Funding
- NIH [R01-HL-74351, HL-68088, HL-70897, HL-76794, HL-78825, HL-55757, HL-91202]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL091202, R01HL074351, R01HL068088, R01HL055757, R01HL076794, P01HL078825, R01HL070897] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Heart failure after myocardial infarction (MI) continues to be the most prevalent cause of morbidity and mortality worldwide. Although pharmaceutical agents and interventional strategies have contributed greatly to therapy, new and superior treatment modalities are urgently needed given the overall disease burden. Stem cell-based therapy is potentially a promising strategy to lead to cardiac repair after MI. An array of cell types has been explored in this respect, including skeletal myoblasts, bone marrow (BM)-derived stem cells, embryonic stem cells, and more recently, cardiac progenitor cells (CPCs). Recently studies have obtained evidence that transplantation of CPCs or BM-derived very small embryonic-like stem cells can improve cardiac function and alleviate cardiac remodeling, supporting the potential therapeutic utility of these cells for cardiac repair. This report summarizes the current data from those studies and discusses the potential implication of these cells in developing clinically-relevant stem cell-based therapeutic strategies for cardiac regeneration. (Circ J 2010; 74: 390-404)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available